Frank Gilberg

3.4k total citations · 2 hit papers
43 papers, 2.3k citations indexed

About

Frank Gilberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Frank Gilberg has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 8 papers in Physiology. Recurrent topics in Frank Gilberg's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (22 papers), Colorectal Cancer Treatments and Studies (10 papers) and Sarcoidosis and Beryllium Toxicity Research (7 papers). Frank Gilberg is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (22 papers), Colorectal Cancer Treatments and Studies (10 papers) and Sarcoidosis and Beryllium Toxicity Research (7 papers). Frank Gilberg collaborates with scholars based in Switzerland, United States and Spain. Frank Gilberg's co-authors include Eric Van Cutsem, Josep Tabernero, Hans‐Joachim Schmoll, Karen Rittweger, Daniel G. Haller, Jean A. Maroun, Filippo de Braud, Klaus-Uwe Kirchgaessler, Timothy Price and Mark Hill and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Frank Gilberg

43 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

2011 533 citations Daniel G. Haller, Josep Tabernero et al. Journal of Clinical Oncology profile →
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

2019 391 citations Toby M. Maher, Tamera J. Corte et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Frank Gilberg

Since Specialization

Citations

This map shows the geographic impact of Frank Gilberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Gilberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Gilberg more than expected).

Fields of papers citing papers by Frank Gilberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Gilberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Gilberg. The network helps show where Frank Gilberg may publish in the future.

Co-authorship network of co-authors of Frank Gilberg

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Gilberg. A scholar is included among the top collaborators of Frank Gilberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Gilberg. Frank Gilberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies 2023 ·Advances in Therapy ·Jürgen Behr, Steven D. Nathan, Ulrich Costabel, Carlo Albera, Wim Wuyts, Marilyn K. Glassberg, (unknown), Giuseppe Alvaro, Frank Gilberg, Katerina Samara, Lisa Lancaster	6
2	Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice 2023 ·SHILAP Revista de lepidopterología ·Robyn H. Guymer, Clare Bailey, Voraporn Chaikitmongkol, Usha Chakravarthy, Varun Chaudhary, Robert P. Finger, Roberto Gallego‐Pinazo, (unknown), Susumu Ishida, (unknown), Mariacristina Parravano, José D. Luna, Steffen Schmitz-Valckenberg, Veeral Sheth, Eric H. Souied, (unknown), Frank Gilberg, Carl Glittenberg, Stefan Scheidl, Monica Bengus	3
3	Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer 2023 ·European Journal of Cancer ·Michel Ducreux, Josep Tabernero, Axel Grothey, Dirk Arnold, Peter J. O’Dwyer, Frank Gilberg, Alexander R. Abbas, Meghna Das Thakur, Hen Prizant, Natsumi Irahara, (unknown), Hans‐Joachim Schmoll, Eric Van Cutsem, Aimery de Gramont	11
4	A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease 2022 ·Respiratory Research ·Toby M. Maher, Courtney Schiffman, Michael Kreuter, Catharina C. Moor, Steven D. Nathan, Judit Axmann, Paula Belloni, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Marlies Wijsenbeek	17
5	MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer 2022 ·ESMO Open ·Josep Tabernero, Axel Grothey, Dirk Arnold, Aimery de Gramont, Michel Ducreux, Peter J. O’Dwyer, (unknown), Frank Gilberg, Natsumi Irahara, Hans‐Joachim Schmoll, Eric Van Cutsem	32
6	Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis 2022 ·Frontiers in Medicine ·María Molina‐Molina, Michael Kreuter, Vincent Cottin, Tamera J. Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M. Maher	3
7	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study 2021 ·Advances in Therapy ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, (unknown), Alessandro Giuseppe Fois, Onofre Moran‐Mendoza, (unknown), (unknown), Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	9
8	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use 2021 ·Advances in Therapy ·Michael Kreuter, Toby M. Maher, Tamera J. Corte, María Molina‐Molina, Judit Axmann, Frank Gilberg, Klaus-Uwe Kirchgaessler, Vincent Cottin	5
9	Home Spirometry as a Primary Endpoint in Clinical Trials: Sensitivity Analyses of a Randomized Controlled Trial of Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease (UILD) 2020 ·Toby M. Maher, Tamera J. Corte, Michael Kreuter, María Molina‐Molina, Judit Axmann, Frank Gilberg, (unknown), Vincent Cottin	3
10	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial 2020 ·The Lancet Respiratory Medicine ·Jürgen Behr, Steven D. Nathan, Wim Wuyts, Nesrin Moğulkoç, Demosthenes Bouros, Κατερίνα Αντωνίου, Julien Guiot, Mordechai R. Kramer, Klaus-Uwe Kirchgaessler, Monica Bengus, Frank Gilberg, (unknown), Sergio Harari, Athol U. Wells	97
11	Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy 2018 ·Annals of Oncology ·Axel Grothey, Josep Tabernero, Dirk Arnold, Aimery de Gramont, Michel Ducreux, Peter J. O’Dwyer, Eric Van Cutsem, (unknown), Stefanie Srock, Christoph Mancao, Frank Gilberg, (unknown), Hans‐Joachim Schmoll	75
12	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study 2018 ·Advances in Therapy ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, Monica Bengus, (unknown), Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	16
13	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design 2018 ·Respiratory Medicine ·Jürgen Behr, Steven D. Nathan, Sergio Harari, Wim Wuyts, Klaus-Uwe Kirchgaessler, Monica Bengus, Frank Gilberg, Athol U. Wells	26
14	Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial 2017 ·The Lancet Oncology ·Brigitte Dréno, Rainer Kunstfeld, Axel Hauschild, Scott W. Fosko, David Zloty, B. Labeille, Jean-Jacques Grob, Susana Puig, Frank Gilberg, (unknown), Damian R. Page, Gary S. Rogers, Dirk Schadendorf	142
15	Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment 2017 ·Pneumologie ·Ulrich Costabel, (unknown), Carlo Albera, (unknown), Frank Gilberg, (unknown)	1
16	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer breakdown → 2011 ·Journal of Clinical Oncology ·Daniel G. Haller, Josep Tabernero, Jean A. Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger, Hans‐Joachim Schmoll	533
17	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients 2011 ·Annals of Oncology ·Jim Cassidy, Leonard B. Saltz, Chris Twelves, Eric Van Cutsem, Paulo M. Hoff, Yoon‐Koo Kang, (unknown), Frank Gilberg, David Cunningham	70
18	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results 2011 ·British Journal of Cancer ·J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz	178
19	Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy 2011 ·Annals of Oncology ·Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy	122
20	Epidemiology and natural history of central venous access device (CVAD) use and infusion pump performance among patients (pts) treated for metastatic colorectal cancer (mCRC): Analysis from the NO16966 trial. 2011 ·Journal of Clinical Oncology ·Eric Chun‐Pu Chu, Daniel G. Haller, Thomas H. Cartwright, C.J. Twelves, Edward McKenna, Nana Scotto, Frank Gilberg, J Cassidy, Wenxue Sun, (unknown), Hans‐Joachim Schmoll	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact